This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Elevation Oncology Stock (NASDAQ:ELEV) Get Elevation Oncology alerts:Sign Up Key Stats Today's Range$0.37▼$0.3750-Day Range$0.36▼$0.3952-Week Range$0.27▼$0.40VolumeN/AAverage Volume1.34 million shsMarket Capitalization$21.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Read More Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELEV Stock News HeadlinesElevation Oncology Terminates License Agreement with CSPCJuly 25, 2025 | theglobeandmail.comElevation Oncology Completes Merger with Concentra BiosciencesJuly 23, 2025 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)ELEV - Elevation Oncology Inc Sustainability | MorningstarJuly 11, 2025 | morningstar.comMHAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)June 15, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of ShareholdersJune 12, 2025 | prnewswire.comELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation ...June 12, 2025 | morningstar.comMHC Wainwright & Co. Downgrades Elevation Oncology (ELEV)June 12, 2025 | msn.comSee More Headlines ELEV Stock Analysis - Frequently Asked Questions How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.04. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $100 million in an initial public offering on Thursday, June 24th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Elevation Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/15/2025Today6/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELEV CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees40Year Founded2019Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.68% Return on Assets-48.14% Debt Debt-to-Equity Ratio0.67 Current Ratio19.40 Quick Ratio19.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book0.36Miscellaneous Outstanding Shares59,220,000Free Float54,427,000Market Cap$21.62 million OptionableOptionable Beta1.48 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ELEV) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
